Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

23.41
+0.19000.82%
Post-market: 23.410.00000.00%18:41 EDT
Volume:472.84K
Turnover:11.12M
Market Cap:1.49B
PE:-8.51
High:23.90
Open:23.34
Low:23.11
Close:23.22
Loading ...

BRIEF-Vera Therapeutics Files For Mixed Shelf Offering

Reuters
·
29 Oct 2024

BRIEF-Vera Therapeutics Announces Proposed Public Offering Of Class A Common Stock

Reuters
·
29 Oct 2024

Vera Therapeutics announces $300M offering of Class A common stock

TIPRANKS
·
29 Oct 2024

Vera Therapeutics Inc - to Commence $300 Million Public Offering

THOMSON REUTERS
·
29 Oct 2024

Vera Therapeutics Announces Proposed Public Offering of Class a Common Stock

THOMSON REUTERS
·
29 Oct 2024

Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dow Jones
·
29 Oct 2024

Vera Therapeutics files automatic mixed securities shelf

TIPRANKS
·
29 Oct 2024

Vera Therapeutics Inc Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing

THOMSON REUTERS
·
29 Oct 2024

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
29 Oct 2024

BUZZ-Vera jumps on additional mid-stage study data for kidney disease drug

Reuters
·
28 Oct 2024

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Benzinga
·
28 Oct 2024

Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study

Dow Jones
·
28 Oct 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Benzinga
·
28 Oct 2024

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

TIPRANKS
·
28 Oct 2024

Promising Clinical Data and Strong Financials Justify Buy Rating for Vera Therapeutics Amid Atacicept’s Potential in IgAN

TIPRANKS
·
28 Oct 2024

BRIEF-Vera Therapeutics Says ORIGIN Phase 2b Trial Met Primary And Secondary Endpoints With Significant Proteinuria Reductions

Reuters
·
27 Oct 2024

Vera Therapeutics Announces 96-Week Egfr Stabilization in Origin Phase 2B Study of Atacicept in Igan in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

THOMSON REUTERS
·
27 Oct 2024

Vera Therapeutics Inc - Pivotal Origin 3 Trial on Track to Announce Topline Results in Q2 2025, With Planned Bla Submission to U.S. FDA Later in Year

THOMSON REUTERS
·
27 Oct 2024

Vera Therapeutics Inc - Trial Met Primary and Secondary Endpoints With Significant Proteinuria Reductions

THOMSON REUTERS
·
27 Oct 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

GlobeNewswire
·
27 Oct 2024